Cargando…

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease

BACKGROUND: Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with true event rates in the Trial Evaluating Cardiovascular O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bethel, M. Angelyn, Sourij, Harald, Stevens, Susanna R., Hannan, Karen, Lokhnygina, Yuliya, Adler, Amanda I., Peterson, Eric D., Holman, Rury R., Lopes, Renato D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054031/ https://www.ncbi.nlm.nih.gov/pubmed/36978066 http://dx.doi.org/10.1186/s12933-023-01802-x

Ejemplares similares

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Progression of glucose‐lowering diabetes therapy in TECOS
por: Bethel, M. Angelyn, et al.
Publicado: (2018)

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
por: Coleman, Ruth L., et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Evaluation of a Self-Administered Oral Glucose Tolerance Test
por: Bethel, M. Angelyn, et al.
Publicado: (2013)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
por: Nauck, Michael A., et al.
Publicado: (2019)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
por: Harumi Higuchi dos Santos, Marilia, et al.
Publicado: (2017)

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
por: Mentz, Robert J., et al.
Publicado: (2018)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
por: Regan, Jessica A., et al.
Publicado: (2023)

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial
por: Kraus, William E, et al.
Publicado: (2018)

The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease
por: Hsuan, Chin-Feng, et al.
Publicado: (2022)

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
por: Hageman, Steven H J, et al.
Publicado: (2022)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
por: Melnikov, Ivan, et al.
Publicado: (2023)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Correction: Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Publicado: (2022)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Atherosclerotic Cardiovascular Disease Beginning in Childhood
por: Hong, Young Mi
Publicado: (2010)

The gut microbiome in atherosclerotic cardiovascular disease
por: Jie, Zhuye, et al.
Publicado: (2017)

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors
por: Miao, Benjamin, et al.
Publicado: (2020)

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus
por: Zhao, Megan, et al.
Publicado: (2023)

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial
por: Price, Hermione C, et al.
Publicado: (2008)

The Roles of Neutrophils Linking Periodontitis and Atherosclerotic Cardiovascular Diseases
por: Irwandi, Rizky A., et al.
Publicado: (2022)

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
por: Mauriello, Alfredo, et al.
Publicado: (2023)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Cardiovascular magnetic resonance in carotid atherosclerotic disease
por: Dong, Li, et al.
Publicado: (2009)

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases
por: Wu, Hongxian, et al.
Publicado: (2018)

Social Network Structure and Atherosclerotic Cardiovascular Disease
por: Nishi, Nobuo
Publicado: (2018)

Incidence of cancers in patients with atherosclerotic cardiovascular diseases
por: Suzuki, Makoto, et al.
Publicado: (2017)

Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease
por: Yu, En, et al.
Publicado: (2018)

Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective
por: Huseynov, Aydin, et al.
Publicado: (2023)

Cardiovascular Changes in Atherosclerotic ApoE-Deficient Mice Exposed to Co60 (γ) Radiation
por: Kumarathasan, Prem, et al.
Publicado: (2013)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9nlcg2pq2tutmn6eri7gfap7r0